Drugs / SR604
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06349473 | May 2024 → Sep 2026 overdue | factor VII deficiency, hemophilia A, hemophilia B | Equilibra Bioscience LLC | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07644832 | May 2024 → Dec 2026 expected | factor VII deficiency, hemophilia A, hemophilia B | Shanghai RAAS Blood Products Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07711158 | Jul 2026 → Feb 2027 expected | congenital factor VII deficiency | Shanghai RAAS Blood Products Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07640893 | Nov 2025 → Dec 2027 expected | von Willebrand disease (hereditary or acquired) | Shanghai RAAS Blood Products Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06349473 ↗ |
| Route | Subcutaneous | “SR604 will be administered as SC injection.” NCT06349473 ↗ |